Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vaxcyte Inc (PCVX)

Vaxcyte Inc (PCVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,803,938
  • Shares Outstanding, K 128,762
  • Annual Sales, $ 0 K
  • Annual Income, $ -463,930 K
  • EBIT $ -570 M
  • EBITDA $ -592 M
  • 60-Month Beta 1.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.82

Options Overview Details

View History
  • Implied Volatility 106.28% ( +0.16%)
  • Historical Volatility 38.30%
  • IV Percentile 93%
  • IV Rank 72.35%
  • IV High 135.29% on 08/06/24
  • IV Low 30.38% on 09/24/24
  • Put/Call Vol Ratio 0.11
  • Today's Volume 111
  • Volume Avg (30-Day) 374
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 10,404
  • Open Int (30-Day) 11,124

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.00
  • Number of Estimates 3
  • High Estimate -0.85
  • Low Estimate -1.15
  • Prior Year -0.85
  • Growth Rate Est. (year over year) -17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
67.23 +11.58%
on 03/11/25
84.01 -10.71%
on 02/21/25
-7.46 (-9.05%)
since 02/20/25
3-Month
67.23 +11.58%
on 03/11/25
93.77 -20.01%
on 01/28/25
-11.52 (-13.31%)
since 12/20/24
52-Week
58.10 +29.10%
on 04/25/24
121.06 -38.04%
on 09/19/24
+5.88 (+8.51%)
since 03/20/24

Most Recent Stories

More News
One Vanguard Index Fund to Buy That May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst

Last November, Fundstrat analyst Tom Lee told CNBC that small-cap stocks are headed for a prolonged period of outperformance compared to the large-cap S&P 500 (SNPINDEX: ^GSPC) . "I think small caps could,...

PCVX : 74.55 (-2.09%)
SSB : 93.82 (-0.61%)
$SPX : 5,649.19 (-0.46%)
FTAI : 106.06 (-2.71%)
MORN : 296.29 (-0.12%)
SFM : 140.76 (-0.04%)
GS : 563.48 (+1.10%)
INSM : 78.70 (-0.30%)
VTWO : 83.17 (-0.55%)
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

PCVX : 74.55 (-2.09%)
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

PCVX : 74.55 (-2.09%)
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

PCVX : 74.55 (-2.09%)
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive

Merck MRK announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate vaccine (PCV),...

PCVX : 74.55 (-2.09%)
MRK : 94.38 (+0.38%)
PFE : 26.12 (-0.34%)
SNY : 57.68 (-1.57%)
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

PCVX : 74.55 (-2.09%)
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and commercialize next-generation pneumococcal conjugate vaccines (PCVs) for treating invasive...

PCVX : 74.55 (-2.09%)
MRK : 94.38 (+0.38%)
PFE : 26.12 (-0.34%)
SNY : 57.68 (-1.57%)
New Vaccine Technologies Lead the Charge as Global Immunization Efforts Evolve

Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – According to the World Health...

PCVX : 74.55 (-2.09%)
BVAXF : 0.0376 (+4.44%)
BIOV.CN : 0.0550 (-8.33%)
GILD : 105.28 (-2.07%)
GOVX : 1.3550 (-3.90%)
ARCT : 12.70 (-5.22%)
1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank

Jefferies analysts have set the S&P 500 (SNPINDEX: ^GSPC) with a 2025 target of 6,000. That forecast implies about 1% downside from its current level of 6,050, which ranks among the most bearish outlooks...

PCVX : 74.55 (-2.09%)
JPM : 239.46 (+0.15%)
$SPX : 5,649.19 (-0.46%)
FTAI : 106.06 (-2.71%)
JEF : 59.15 (-0.25%)
SFM : 140.76 (-0.04%)
MLI : 80.25 (-1.47%)
GS : 563.48 (+1.10%)
INSM : 78.70 (-0.30%)
VTWO : 83.17 (-0.55%)
Why Wall Street Rates These 2 Russell 2000 Stocks a “Strong Buy”

These two biotech companies look poised to deliver in the coming year.

PCVX : 74.55 (-2.09%)
$SPX : 5,649.19 (-0.46%)
MRK : 94.38 (+0.38%)
AIT : 230.91 (+0.28%)
PFE : 26.12 (-0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.

See More

Key Turning Points

3rd Resistance Point 79.50
2nd Resistance Point 77.94
1st Resistance Point 77.04
Last Price 74.55
1st Support Level 74.58
2nd Support Level 73.02
3rd Support Level 72.12

See More

52-Week High 121.06
Fibonacci 61.8% 97.01
Fibonacci 50% 89.58
Fibonacci 38.2% 82.15
Last Price 74.55
52-Week Low 58.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar